Both recreational and problematic 3,4-methylenedioxymethamphetamine (MDMA)/ecstasy users could benefit from employing harm reduction interventions intended to preserve health and prevent negative consequences. To evaluate whether use of such interventions varied by country of residence and frequency of ecstasy use, we used web-based surveys to assess how often 104 lower-frequency and higher-frequency American ecstasy users and 80 lower-frequency and higher-frequency British ecstasy users employed each of 19 self-initiated harm reduction strategies when they used ecstasy during a 2-month period. Several significant differences notwithstanding, at least 75% of participants had used 11 of the 19 strategies one or more times during the 2-month assessment period, regardless of whether they lived in the United States or United Kingdom and whether they were lower-frequency or higher-frequency ecstasy users. When proportions of American and British participants using a strategy differed significantly, it was typically larger proportions of Americans using those strategies. Many of the less frequently employed strategies are not applicable on every occasion of ecstasy use. However, because ecstasy is not a diverted pharmaceutical of known quality/potency, testing for the presence of MDMA, other stimulants, and adulterants is a strategy that everyone should employ, regardless of country of residence or how frequently one consumes ecstasy.
Introduction 3,4-methylenedioxymethamphetmine (MDMA), frequently referred to as ''ecstasy'' or ''molly,'' is used by millions of people around the world (United Nations Office on Drugs and Crime, 2014). Among Englishspeaking countries in the Northern Hemisphere, use of ecstasy is more prevalent among young adults in the United States (3.5% among 18-25 year olds; Center for Behavioral Health Statistics and Quality, 2015) and the United Kingdom (4% among 15-34 year olds; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2011, 2016) than it is in Canada (2.6% among 15-24 year olds; Canadian Alcohol and Drug Use Monitoring Survey, 2012) and Republic of Ireland (1% among 15-34 year olds, EMCDDA, 2016) .
Use of MDMA is driven by desirable outcomes of consumption, including increased energy, sociability, self-confidence, stress reduction, sexual enhancement, positive mood, and subjective wellbeing (Baylen and Rosenberg, 2006; Carhart-Harris and Nutt, 2010; Hunt and Evans, 2008; Morgan et al., 2013; Singer and Schensul, 2011; ter Bogt and Engels, 2005; White et al., 2006) . However, many also report acute and delayed negative effects such as dehydration, hyperthermia, tachycardia, nausea, bruxism, dizziness, muscle aches or tightness, sleeplessness, fatigue, confusion, anxiety, depression, and memory and executive function problems (e.g. Amoroso, 2016; Chinet et al., 2007; Rogers et al., 2009; Singer and Schensul, 2011) .
Given the potential biomedical and psychosocial consequences of consuming MDMA, and that multiple substances sold as ecstasy may include adulterants, both recreational and problematic users could benefit from employing self-initiated harm reduction strategies designed to minimize the injurious physiological, psychological, and/or social effects of consumption (Marlatt et al., 2012) . Examples of self-initiated strategies that could be employed by ecstasy users include reducing use of other substances when consuming ecstasy, drinking water or other electrolyte-rich beverages to stay hydrated, having a trusted friend to talk to if one experiences negative emotions or cognitions, reducing the amount of ecstasy consumed during a session, using a test-kit or checking an online drug checking database to see if there are other substances in one's ecstasy, and consuming vitamins, antioxidants, or 5-hydroxytryptophan before or after using ecstasy (pre-loading/post-loading) to attenuate physical or neurological damage associated with consumption (Allot and Redman, 2006; Henry and Rella, 2001; Kelly, 2009; Panagopoulos and Ricciardelli, 2005) .
These harm reduction strategies have the potential to reduce ecstasy-related harms, but one factor that could influence the use of such strategies is the frequency with which ecstasy users consume the substance and, therefore, how often they are exposed to potential harms associated with intoxication. For example, those who consume ecstasy less frequently may not see themselves as being at risk for harmful consequences and therefore may employ harm reduction strategies less often compared to those who consume the substance more frequently. In addition, the proportion of users who employ these strategies could vary by country as a result of widespread professional (and perhaps non-professional) acceptance of harm reduction in the United Kingdom (Rosenberg et al., 2002 (Rosenberg et al., , 2004 compared to the United States (Rosenberg and Davis, 2014; Rosenberg and Phillips, 2003) . Therefore, to evaluate whether frequency of ecstasy consumption (higher or lower) and country of residence (US or UK) were associated with use of ecstasy-specific harm reduction strategies, we compared the proportions of American and British higher-frequency and lower-frequency ecstasy users who had employed each of 19 strategies when they used ecstasy during a 2-month period.
Method

Procedure and participant recruitment
As part of a prospective study evaluating psychological characteristics associated with later use of two ecstasy-specific harm reduction strategies (Davis and Rosenberg, 2016) , we recruited two separate samples of ecstasy users (October-November 2013 and May-June 2014). For both waves of data collection, announcements describing the study and directing potential participants to the web-based study materials were distributed using targeted advertisements on Facebook and postings on other websites, such as reddit.com, pillreports.com, bluelight.org, and dancesafe.org. Once at the study site, hosted by Survey Gizmo, participants were presented with an informed consent document approved by our institutional review board and a series of questionnaires to assess their attitudes regarding use of ecstasy-related harm reduction strategies. Approximately 2 months later, we contacted participants by email to evaluate how many times they had consumed ecstasy since baseline and the proportion of times they had employed each of 19 harm reduction strategies when they consumed ecstasy during the study.
As incentives to participate, we informed potential participants in the first wave that we would donate $5.00 per participant, up to a maximum of $250, to bluelight.org (a forum for drug users that is committed to reducing harm associated with substance use), and we offered a $10.00 Starbucks card to the first 160 participants who completed the follow-up assessment in the second wave. Across both waves of assessment, 729 ecstasy users completed baseline measures. Of these, 236 (32%) responded to the follow-up invitation, consumed ecstasy during the previous 2 months, and completed the follow-up assessment measures. However, 52 of these individuals were from countries other than the US or UK, and thus were excluded from the final sample of 184 participants retained in the present analysis.
Baseline measures
Ecstasy and substance use history questionnaire. We created a questionnaire to assess both ecstasy and other drug use history variables. Specifically, we asked participants the frequency of their MDMA/ecstasy use, how many times they had used MDMA/ecstasy in the previous 3 months, the number of times they had used in their lifetime, where they typically consumed MDMA/ ecstasy, and the last time they used. We also asked participants to indicate whether they had or had not consumed other drugs (e.g. alcohol, nicotine, cannabis/ marijuana, synthetic cannabinoids) at least once during the 3 months prior to baseline.
Demographic questionnaire. We created this questionnaire to assess participants' country of residence, gender, age, sexual orientation, ethnicity, education level, and relationship status.
Follow-up measures
Ecstasy harm reduction strategies questionnaire. Based on previously published research regarding specific harm reduction interventions employed by users of ecstasy (Allot and Redman, 2006; Henry and Rella, 2001; Panagopoulos and Ricciardelli, 2005) , we devised this questionnaire to assess the proportion of occasions participants had used each of 19 ecstasy-specific harm reduction strategies (see Table 2 for list) when they consumed MDMA/ecstasy since baseline. Because over 80% of participants had used ecstasy 4 or fewer times in the 2-month follow-up period, we dichotomized responses as indicating use or no use of each of the 19 strategies to calculate how many participants had employed each strategy at least once during the 2-month assessment period.
Ecstasy use during 2-month follow-up. We administered a single question asking participants how many times they had consumed MDMA/ecstasy since baseline.
Data analysis plan
First, we conducted chi-square and Fisher's exact analyses to compare participants residing in each country (US versus UK) on demographic, ecstasy use, and other substance use history variables. Next, we calculated the proportion of American and British lowerfrequency users (defined as consuming ecstasy 1-2 times since baseline) and proportion of higher-frequency users (defined as consuming ecstasy 3-or-more times since baseline) who had used each strategy at least once during the 2-month follow-up period. For each of the 19 strategies, we calculated four 2-proportion ztests to evaluate whether (a) American lower-frequency users differed from American higher-frequency users; (b) British lower-frequency users differed from British higher-frequency users; (c) American lower-frequency users differed from British lower-frequency users; and (d) American higher-frequency users differed from British higher-frequency users. Given the limitations of employing a Bonferroni-corrected alpha (e.g. the testing of an irrelevant null hypothesis [study-wide error rate] and increasing the likelihood of Type II error; Perniger, 1998), we used an alpha level of .05 to determine whether statistical tests were significant.
Results
Participant characteristics
Examination of Table 1 reveals that both subsamples were comprised primarily of Caucasians (US ¼ 78%; UK ¼ 89%), males (US ¼ 72%; UK ¼ 85%), and 18-to 24-year olds (US¼ 71%; UK ¼ 71%). Approximately one-half of both subsamples consumed ecstasy once per month or more prior to baseline, and a little over onehalf had consumed ecstasy 20 or more occasions throughout their lifetime. Large proportions of both subsamples reported that they also had consumed alcohol (US ¼ 93%; UK ¼ 96%) and cannabis (US ¼ 84%; UK ¼ 80%) in the 3 months prior to baseline assessment. There were no statistically significant associations between levels of demographic or ecstasy use history characteristics and country of residence, with the exception of gender (i.e. larger proportion of males in the UK sample).
Proportions employing strategies by country and frequency of ecstasy consumption
As examination of Table 2 reveals, 11 of the 19 strategies had been used one or more times during the 2-month assessment period by at least 75%, and often by more than 90%, of the participants regardless of country of residence or frequency of ecstasy consumption. Of those 11 strategies employed by a large majority of participants, two (#10 and #6) differed significantly, but not meaningfully, by country of residence or frequency of ecstasy use. Of the eight strategies used by relatively smaller proportions of participants, three (# 8, # 5, #4) had been employed one or more times by at least 50% of participants, and there were no significant differences in the proportions within country or across country by frequency of ecstasy use. Of the five remaining strategies employed by smaller proportions of participants, a larger proportion of higher-frequency American ecstasy users employed the pill testing/drug checking (#3) and the pre-loading/post-loading (#2) strategies than did higher-frequency British ecstasy users. In addition, a higher proportion of lower-frequency British ecstasy users employed the pill-testing/drug-checking (#3) strategy than did the higher-frequency British ecstasy users, but a smaller proportion of lower-frequency British ecstasy users took a chill-out break because of bad thoughts (#9) compared to higher-frequency British ecstasy users. Finally, a larger proportion of lowerfrequency American ecstasy users stretched their muscles (#17) compared to lower-frequency British ecstasy users.
Strategies employed by participants that were not listed on the questionnaire
In response to an open-ended question asking participants to report any other strategies they employed to reduce or ameliorate the potential harms associated with ecstasy consumption, 34 participants from the US and 22 from the UK provided a response. Aside from responses similar or identical to items listed on the questionnaire, new strategies reported by more than one participant from the US included limiting number of doses within a session (n ¼ 4), using only in specific locations (e.g. home, festival, club; n ¼ 4), maintaining a healthy diet (n ¼ 4), physical exercise (n ¼ 3), resting the day after consumption (n ¼ 3), and chewing gum (n ¼ 2). In addition to repeating some of the 19 listed strategies, new strategies reported by more than one participant from the UK included eating a healthy diet prior to and following consumption (n ¼ 3), measuring exact dose (n ¼ 2), limiting dose within a session (n ¼ 2), and keeping their cell phone charged (n ¼ 2).
Discussion
Using a more extensive list of ecstasy-related and other harm reduction strategies than previously published investigations (Allot and Redman, 2006; Chinet et al., 2007; Henry and Rella, 2001; Jacinto et al., 2008; Panagopoulos and Ricciardeli, 2005; Shewan et al., 2000) , we found that recreational MDMA/ecstasy users employed a wide range of harm reduction strategies to manage the potential injurious effects of acute intoxication. Specifically, at least three quarters (and often more than 90%) of participants had employed 11 of 19 harm reduction strategies at least once during a 2-month assessment period, whether they lived in the US or UK and whether they were loweror higher-frequency ecstasy users. Contrary to our expectation, and several significant differences notwithstanding, there were few meaningful differences in the proportions of lower-frequency versus higher-frequency users who employed most of the listed strategies. Perhaps those who used ecstasy less frequently did so, in part, as a form of harm reduction in itself, and were no less concerned about or aware of the value of these interventions than higher-frequency users. We also found relatively few and notably minor differences in the proportions of British versus American participants who used each of the 19 strategies. Although harm reduction has been more acceptable to professionals in the UK than to professionals in the US, American ecstasy users apparently recognize the value of harm reduction even if the American treatment industry promotes abstinence and discourages safer consumption practices. Furthermore, social support and information about harm reduction is readily available via the Internet to recreational users living in both countries, which likely has broad implications in user acceptability.
The results from the present study should be considered in light of several methodological limitations. First, we employed a web-based recruitment and data collection procedure and the proportion of ecstasy users who implement harm reduction strategies may have been lower among the non-responders and users who were unable or unwilling to participate in internetbased research. Second, we asked participants to report their use of harm reduction strategies when they consumed ecstasy during a 2-month period and their memories could have been influenced by both the passage of time and the acute effects of intoxication at the time they reportedly employed these strategies. Third, our study was comprised of relatively small samples of primarily young Caucasian men from only two countries, and the frequency with which women, individuals from diverse ethnic backgrounds, and from other parts of the world use these strategies warrants further investigation.
We recognize these findings may be limited to users with similar demographic and drug history characteristics, but that such high proportions of our participants used 11 of these 19 strategies implies that there is little need to encourage younger, male, web savvy ecstasy users to employ these particular strategies. Of the remaining eight strategies, some may have been used less frequently because they were irrelevant given the circumstances or contexts in which the person consumes ecstasy (e.g. chill out break because of bad thoughts and emotions; stretch muscles prior to consumption). However, other less frequently used harm reduction strategies may apply to every user regardless of context. For example, because ecstasy is not a diverted pharmaceutical of known quality and potency, testing for the presence of MDMA, other stimulants, and adulterants is a strategy that everyone should employ, regardless of country of residence or how frequently one consumes ecstasy. Therefore, we suggest that prevention specialists, harm reduction workers, and clinicians in the US and the UK encourage ecstasy users to use drug testing services (where available), personal drug testing kits (which can be purchased on the internet), and drug checking websites (e.g. pillreports.org). Because we recognize that high quality testing facilities are not always available, that home testing kits may be unreliable or misinterpreted, and that online drug-checking sites may not reveal up-to-date information about current batches of ecstasy, we also recommend that researchers evaluate the efficacy and the economic and health-related benefits of drug checking to develop an empirical basis to support policy changes and to provide funding for such services. Lastly, that many ecstasy users in the US and the UK consume a variety of substances either separately or simultaneously, we recommend further evaluation of harm reduction strategies that reduce harms associated with consumption of multiple substances.
